Your browser doesn't support javascript.
loading
Preformed Donor-Specific HLA Antibodies in Living and Deceased Donor Transplantation: A Multicenter Study.
Ziemann, Malte; Altermann, Wolfgang; Angert, Katharina; Arns, Wolfgang; Bachmann, Anette; Bakchoul, Tamam; Banas, Bernhard; von Borstel, Annette; Budde, Klemens; Ditt, Vanessa; Einecke, Gunilla; Eisenberger, Ute; Feldkamp, Thorsten; Görg, Siegfried; Guthoff, Martina; Habicht, Antje; Hallensleben, Michael; Heinemann, Falko M; Hessler, Nicole; Hugo, Christian; Kaufmann, Matthias; Kauke, Teresa; Koch, Martina; König, Inke R; Kurschat, Christine; Lehmann, Claudia; Marget, Matthias; Mühlfeld, Anja; Nitschke, Martin; Pego da Silva, Luiza; Quick, Carmen; Rahmel, Axel; Rath, Thomas; Reinke, Petra; Renders, Lutz; Sommer, Florian; Spriewald, Bernd; Staeck, Oliver; Stippel, Dirk; Süsal, Caner; Thiele, Bernhard; Zecher, Daniel; Lachmann, Nils.
Affiliation
  • Ziemann M; Institute for Transfusion Medicine and.
  • Altermann W; Institute for Transfusion Medicine, University Hospital Halle, Halle, Germany.
  • Angert K; Institute for Transfusion Medicine and.
  • Arns W; Clinic for Internal Medicine I, Kliniken der Stadt Köln, Cologne, Germany.
  • Bachmann A; Medical Department III - Endocrinology, Nephrology, Rheumatology and.
  • Bakchoul T; Institute for Transfusion Medicine and.
  • Banas B; Department of Nephrology, University Hospital Regensburg, Regensburg, Germany.
  • von Borstel A; Institute for Transfusion Medicine, Kliniken der Stadt Köln, Cologne, Germany.
  • Budde K; Division of Nephrology and Internal Intensive Care Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany.
  • Ditt V; Institute for Transfusion Medicine, Kliniken der Stadt Köln, Cologne, Germany.
  • Einecke G; Clinic for Renal and Hypertensive Disorders and.
  • Eisenberger U; Clinic for Nephrology and.
  • Feldkamp T; Transplant Center, University Hospital of Schleswig-Holstein, Kiel, Germany.
  • Görg S; Institute for Transfusion Medicine and.
  • Guthoff M; Section for Renal and Hypertensive Disorders, Clinic for Internal Medicine IV, University Hospital Tübingen, Tübingen, Germany.
  • Habicht A; Transplant Center.
  • Hallensleben M; Institute for Transfusion Medicine, Medizinische Hochschule Hannover, Hannover, Germany.
  • Heinemann FM; Institute for Transfusion Medicine, University Hospital Essen, Essen, Germany.
  • Hessler N; Institute of Medical Biometry and Statistics, University Medical Center Schleswig-Holstein Lübeck, Germany.
  • Hugo C; Clinic for Internal Medicine III, University Hospital Carl Gustav Carus, Dresden, Germany.
  • Kaufmann M; Regional Office North, German Organ Transplantation Foundation, Hannover, Germany.
  • Kauke T; Department of General, Visceral, Vascular, and Transplant Surgery and.
  • Koch M; Department for Transfusion Medicine, Hospital of the Ludwig-Maximilians-University München München, Germany.
  • König IR; Department for Transfusion Medicine, Hospital of the Ludwigs-Maximilians-University München, München, Germany.
  • Kurschat C; Department of Visceral Transplantation and.
  • Lehmann C; Institute of Medical Biometry and Statistics, University Medical Center Schleswig-Holstein Lübeck, Germany.
  • Marget M; Second Department of Internal Medicine, Transplant Center and.
  • Mühlfeld A; Institute for Transfusion Medicine, University Hospital Leipzig, Leipzig, Germany.
  • Nitschke M; Institute for Transfusion Medicine, University Hospital Hamburg, Hamburg, Germany.
  • Pego da Silva L; Clinic for Renal and Hypertensive Disorders, Rheumatological and Immunological Diseases, University Hospital Aachen, Aachen, Germany.
  • Quick C; Transplant center, University Hospital of Schleswig-Holstein, Lübeck, Germany.
  • Rahmel A; Department of Internal Medicine-Nephrology and.
  • Rath T; Clinic for Internal Medicine III, University Hospital Carl Gustav Carus, Dresden, Germany.
  • Reinke P; German Organ Transplantation Foundation, Frankfurt, Germany.
  • Renders L; Department for Nephrology and Transplantation, Westpfalz-Klinikum, Kaiserslautern, Germany.
  • Sommer F; Division of Nephrology and Internal Intensive Care Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany.
  • Spriewald B; Department for Nephrology, Klinikum Rechts der Isar der Technischen Universität München, Munich, Germany.
  • Staeck O; Department of General, Visceral, and Transplant Surgery, Klinikum Augsburg, Augsburg, Germany.
  • Stippel D; Department of Medicine 5 - Hematology and Oncology, University Hospital Erlangen, Erlangen, Germany.
  • Süsal C; Division of Nephrology and Internal Intensive Care Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany.
  • Thiele B; Department of General, Visceral Surgery and Surgical Oncology, University Hospital Cologne, Cologne, Germany.
  • Zecher D; Institute of Immunology and Transplant Immunology, University Hospital, Heidelberg, Heidelberg, Germany.
  • Lachmann N; Institut für Immunologie und Genetik Kaiserslautern, Kaiserslautern, Germany; and.
Clin J Am Soc Nephrol ; 14(7): 1056-1066, 2019 07 05.
Article in En | MEDLINE | ID: mdl-31213508
ABSTRACT
BACKGROUND AND

OBJECTIVES:

The prognostic value of preformed donor-specific HLA antibodies (DSA), which are only detectable by sensitive methods, remains controversial for kidney transplantation. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS The outcome of 4233 consecutive kidney transplants performed between 2012 and 2015 in 18 German transplant centers was evaluated. Most centers used a stepwise pretransplant antibody screening with bead array tests and differentiation of positive samples by single antigen assays. Using these screening results, DSA against HLA-A, -B, -C, -DRB1 and -DQB1 were determined. Data on clinical outcome and possible covariates were collected retrospectively.

RESULTS:

Pretransplant DSA were associated with lower overall graft survival, with a hazard ratio of 2.53 for living donation (95% confidence interval [95% CI], 1.49 to 4.29; P<0.001) and 1.59 for deceased donation (95% CI, 1.21 to 2.11; P=0.001). ABO-incompatible transplantation was associated with worse graft survival (hazard ratio, 2.09; 95% CI, 1.33 to 3.27; P=0.001) independent from DSA. There was no difference between DSA against class 1, class 2, or both. Stratification into DSA <3000 medium fluorescence intensity (MFI) and DSA ≥3000 MFI resulted in overlapping survival curves. Therefore, separate analyses were performed for 3-month and long-term graft survival. Although DSA <3000 MFI tended to be associated with both lower 3-month and long-term transplant survival in deceased donation, DSA ≥3000 MFI were only associated with worse long-term transplant survival in deceased donation. In living donation, only strong DSA were associated with reduced graft survival in the first 3 months, but both weak and strong DSA were associated with reduced long-term graft survival. A higher incidence of antibody-mediated rejection within 6 months was only associated with DSA ≥3000 MFI.

CONCLUSIONS:

Preformed DSA were associated with an increased risk for graft loss in kidney transplantation, which was greater in living than in deceased donation. Even weak DSA <3000 MFI were associated with worse graft survival. This association was stronger in living than deceased donation.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Tissue Donors / Kidney Transplantation / Living Donors / HLA Antigens / Isoantibodies Type of study: Clinical_trials / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Clin J Am Soc Nephrol Journal subject: NEFROLOGIA Year: 2019 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Tissue Donors / Kidney Transplantation / Living Donors / HLA Antigens / Isoantibodies Type of study: Clinical_trials / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Clin J Am Soc Nephrol Journal subject: NEFROLOGIA Year: 2019 Document type: Article
...